ProfileGDS5678 / 1442612_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 65% 65% 64% 65% 69% 71% 67% 65% 64% 66% 64% 67% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1262267
GSM967853U87-EV human glioblastoma xenograft - Control 23.9034265
GSM967854U87-EV human glioblastoma xenograft - Control 33.9194165
GSM967855U87-EV human glioblastoma xenograft - Control 43.8201564
GSM967856U87-EV human glioblastoma xenograft - Control 53.8987265
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2641569
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4642371
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0418967
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8818965
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8466264
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9538966
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.849364
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0372967
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9692966